Puma Biotechnology, Inc.
NASDAQ•PBYI
CEO: Mr. Alan H. Auerbach
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2012-04-24
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Contact Information
10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, 90024, United States
424-248-6500
Market Cap
$323.51M
P/E (TTM)
8.7
37
Dividend Yield
--
52W High
$7.21
52W Low
$2.58
52W Range
Rank65Top 96.0%
1.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$54.48M-32.36%
4-Quarter Trend
EPS
$0.18-56.10%
4-Quarter Trend
FCF
$9.66M-12.30%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Net Income Significantly Rises Net Income reached $17.7M for nine months ended September 30, 2025, significantly increasing from $11.0M last year.
Product Revenue Shows Growth Net Product Revenue grew to $144.2M for nine months, driven by US sales increases despite royalty decline.
Debt Paid Down Operating cash flow provided $27.4M over nine months; long-term debt reduced to zero net balance.
Risk Factors
Royalty Revenue Collapse Royalty revenue plummeted $21.9M for nine months due to reduced international licensee sales activity, impacting total revenue.
Key Patent Litigation Setback Key NERLYNX patents invalidated by court ruling in AstraZeneca suit; appeal process is ongoing with uncertain outcome.
Increased R&D Spending R&D expenses rose $5.5M for nine months, driven by increased alisertib clinical trial activity requiring capital.
Outlook
Ali Sertib Development Focus Continue global development of alisertib, focusing initial trials on small cell lung cancer indications in 2025.
Sufficient Cash Runway Existing cash and marketable securities totaling $94.4M support operating needs for at least one year post-filing.
NERLYNX Global Expansion Pursue NERLYNX commercialization in over 40 countries via exclusive sub-license agreements globally.
Peer Comparison
Revenue (TTM)
$212.00M
IVA$32.75M
$17.17M
Gross Margin (Latest Quarter)
100.0%
77.7%
HUMA65.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| VTYX | $1.01B | -9.4 | -48.1% | 4.7% |
| ALLO | $386.54M | -1.8 | -57.8% | 19.4% |
| TECX | $377.32M | -5.6 | -27.1% | 0.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.7%
Flat Growth
4Q Net Income CAGR
-22.9%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 26, 2026
EPS:$0.24
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 6, 2025|Revenue: $54.48M-32.4%|EPS: $0.18-56.1%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 7, 2025|Revenue: $52.44M+11.4%|EPS: $0.12-227.9%BeatForm 10-Q/A - Q1 2025
Period End: Mar 31, 2025|Filed: Aug 7, 2025|Revenue: $46.01M+5.1%|EPS: $0.06-160.1%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 8, 2025|Refer to amended dataForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 27, 2025|Revenue: $230.47M-2.2%|EPS: $0.62+34.8%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 7, 2024|Revenue: $80.54M+43.5%|EPS: $0.41+241.7%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 1, 2024|Revenue: $47.08M-13.7%|EPS: $-0.09-306.2%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 2, 2024|Revenue: $43.77M-17.1%|EPS: $-0.10-433.0%Beat